Milciclib - CAS 802539-81-7
Catalog number:
802539-81-7
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
CDK
Description:
Milciclib is an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA is mutated in a variety of cancer cell types.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Appearance:
Light yellow to yellow solid
Synonyms:
PHA-848125; PHA848125; PHA 848125; PHA-848125AC; PHA 848125AC; PHA848125AC
MSDS:
Inquire
Current Developer:
Nerviano Medical Sciences.
1.Epidemiological Surveillance of Leishmaniasis in Montenegro, 1992-2013.
Medenica S, Jovanović S, Dožić I, Milicić B, Lakićević N, Rakocević B. Srp Arh Celok Lek. 2015 Nov-Dec;143(11-12):707-11.
INTRODUCTION: The diseases caused by Leishmania are spread worldwide and represent a significant public health problem.
2.INTRAOPERATIVE ANEURYSMAL RUPTURE: CLINICAL OUTCOME FOLLOWING OPEN SURGERY OR ENDOVASCULAR TREATMENT.
Lakićević N, Prstojević B, Rasulić L, Vujotić L, Vukašinović Ivan, Miličić B, Savić A, Živković B, Rotim K, Samardžić M. Acta Clin Croat. 2015 Sep;54(3):285-94.
The aim of this study was to evaluate and compare the outcomes of intraoperative aneurysmal rupture in patients with subarachnoid hemorrhage undergoing open surgical or endovascular treatment. This retrospective study included 742 patients with aneurysmal subarachnoid hemorrhage treated at the Clinical Department of Neurosurgery, Clinical Center of Serbia, during a three-year period. Among them, 167 (31.15%) were treated by clipping and 33 (16.01%) by coiling in the early phase (≤72 hours). The overall outcome and pretreatment variables were analyzed for each group, including between-group difference according to the occurrence of intraoperative aneurysmal rupture. Intraoperative aneurysmal rupture occurred in 14.7% of microsurgical and 2.4% of endovascular procedures. It was more frequent in early procedures as compared with delayed procedures (27.5% and 9.7% vs. 2.2% and 1.1%, respectively). On the contrary, mortality rates were lower in the surgical group (11.
3.Analysis of cervical resistance during continuous controllable balloon dilatation: controlled clinical and experimental study.
Arsenijevic P1, Milosevic M2, Zivanovic A3, Milicic B4, Jeremic B5, Filipovic N6, Protrka Z7, Todorovic P8, Arsenijevic S9. Trials. 2015 Oct 28;16:485. doi: 10.1186/s13063-015-1003-8.
BACKGROUND: Hydraulic dilatation is a novel method of cervical dilatation that is based on continuous controllable dilatation (CCBD) by the pumping of fluid into the balloon extension of the system. The main advantage of this procedure is that it allows control of and insight into the process of cervical dilatation.
4.Impact of the lower third molar and injury mechanism on the risk of mandibular angle and condylar fractures.
Antic S1,2, Milicic B3,4, Jelovac DB5, Djuric M2. Dent Traumatol. 2016 Jan 28. doi: 10.1111/edt.12259. [Epub ahead of print]
BACKGROUND: Previous studies have shown the influence of the mandibular third molar on mandibular angle and condylar fractures, but have not comparatively analyzed the impact of the injury mechanism on these fractures. The purpose of this study was to evaluate the influence of the lower third molar (M3) and injury-related factors (fracture etiology and site of impact of the traumatic force) on the risk of mandibular angle and condylar fractures.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CDK Products


Senexin A
(CAS: 1366002-50-7)

Senexin A is a selective Cell division protein kinase 8 (CDK8) inhibitor with IC50 value of 280 nM. Senexin A can bind to cdk19 in an ATP-competitive manner and...

KH-CB19
(CAS: 1354037-26-5)

KH-CB19, a CLK1/CLK4 inhibitor, has been found to probably restrain the phosphorylation of serine- and arginine-rich (SR) proteins. IC50: 20 nM for CLK1.

CAS 902135-91-5 AT7519 HCl

AT7519 HCl
(CAS: 902135-91-5)

CAS 186692-46-6 Seliciclib

Seliciclib
(CAS: 186692-46-6)

Seliciclib is an orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential proapoptotic and antineoplastic activities. Selicicl...

CAS 1414943-88-6 BAY-1143572

BAY-1143572
(CAS: 1414943-88-6)

BAY 1143572 is a highly selective, potent and orally available inhibitor ofPTEFb/CDK9 and shows convincing anti-tumor activity in multiple xenograft models by t...

CAS 161058-83-9 NU2058

NU2058
(CAS: 161058-83-9)

NU2058 is a potent CDK inhibitor. which has CDK2 IC(50)=17 microM and CDK1 IC(50)=26 microM.

CAS 784210-87-3 RGB-286638

RGB-286638
(CAS: 784210-87-3)

RGB-286638 is a novel CDK inhibitor. It inhibited several tyrosine and serine/threonine non-CDK enzymes, i.e. GSK-3β, TAK1, AMPK, Jak2, MEK1. It demonstrated eq...

CAS 146426-40-6 Alvocidib

Alvocidib
(CAS: 146426-40-6)

Alvocidib is a synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by p...

CAS 345627-80-7 SNS-032

SNS-032
(CAS: 345627-80-7)

SNS-032, also known as BMS-387032, is a 2-aminothiazole-derived, small-molecule cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. ...

LOR-253
(CAS: 916151-99-0)

LOR-253 is a novel small molecule with potent anti-tumor activity in cancer cells via induction of the gene that expresses the Krüppel-like factor 4 (KLF4) mast...

ON123300
(CAS: 1357470-29-1)

ON123300, a dihydropyrido[2,3-d]pyrimidine derivative, has been found to be an effective multikinase inhibitor that could be probably used against brain tumor a...

CGP74514A
(CAS: 190653-73-7)

CGP74514A is a cell permeable Cdk inhibitor selective for Cyclin-dependent kinase-1 (Cdk1) (IC50=25nM). CGP74514A was also reported also to affect the activitie...

CAS 718630-59-2 PHA-793887

PHA-793887
(CAS: 718630-59-2)

PHA-793887 is an inhibitor of multiple cyclin dependent kinases (CDK) with activity against CDK2, CDK1 and CDK4. Although toxicity was acceptable at initial dos...

CAS 189232-42-6 Bohemine

Bohemine
(CAS: 189232-42-6)

Bohemine, structurally similar to Olomoucine and Roscovitine, is a 2,6,9-trisubstituted purine derivative that inhibits cyclin-dependent kinases (CDKs) and exhi...

CAS 902156-99-4 NVP-LCQ195

NVP-LCQ195
(CAS: 902156-99-4)

NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5. It induced cell cycle arrest and eventual apoptotic cell death of MM cells, ...

CDK9-IN-6
(CAS: 1391855-95-0)

CDK9-IN-6, one of the CDK9 inhibitors, probably have potential activity in influencing cell cycle of T-type cells.

CAS 1211443-80-9 LEE011 hydrochloride

LEE011 hydrochloride
(CAS: 1211443-80-9)

CDK4/6 inhibitor LEE011 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation preve...

CAS 802539-81-7 Milciclib

Milciclib
(CAS: 802539-81-7)

Milciclib is an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activi...

THZ1-R
(CAS: 1621523-07-6)

THZ1-R, with the potential to treat Triple-negative breast cancer (TNBC), it is a potent and selective CDK7 inhibitor but has instability in vivo.

CAS 142273-20-9 Kenpaullone

Kenpaullone
(CAS: 142273-20-9)

Kenpaullone is a potent inhibitor of CDK1/cyclin B (IC50 = 400 nM), CDK2/cyclin A (IC50 = 680 nM), CDK2/cyclin E (IC50 = 7.5 uM) and CDK5/p25 (IC50 = 850 nM). K...

Chemical Structure

CAS 802539-81-7 Milciclib

Quick Inquiry

Verification code

Featured Items